Zollinger‑Ellison syndrome (MEN1-associated) - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Zollinger‑Ellison Syndrome (MEN‑1 Associated) – Complete Guide

Zollinger‑Ellison Syndrome (MEN‑1 Associated)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare condition in which one or more gastrin‑producing tumors called gastrinomas develop in the pancreas or duodenum. The excess gastrin stimulates the stomach to secrete large amounts of gastric acid, leading to severe peptic ulcer disease and other gastrointestinal problems. When ZES occurs as part of multiple endocrine neoplasia type 1 (MEN‑1), patients also have a hereditary predisposition to develop tumors in the parathyroid glands, pituitary gland, and other endocrine organs.

  • Who it affects: Both men and women; onset typically occurs in the 3rd–5th decade of life, but MEN‑1‑related cases can be identified in adolescence.
  • Prevalence: Sporadic ZES occurs in ~1–3 per million people worldwide. Approximately 20–30 % of ZES cases are MEN‑1‑associated, making MEN‑1 the single most common hereditary cause of gastrinomas.1
  • Genetics: MEN‑1 is autosomal dominant; a pathogenic mutation in the MEN1 tumor suppressor gene (located on chromosome 11q13) is found in >90 % of families.2

Symptoms

Symptoms arise from acid hypersecretion and from the tumor itself. They can vary widely, so clinicians use a comprehensive checklist.

Gastrointestinal Symptoms

  • Refractory peptic ulcers – often multiple, located beyond the duodenum (e.g., jejunum, ileum).
  • Abdominal pain – burning or gnawing pain that may worsen after meals.
  • Diarrhea – watery, sometimes greasy stools due to acid‑induced malabsorption.
  • Heartburn / gastro‑esophageal reflux disease (GERD).
  • Nausea and vomiting – can be chronic or episodic.
  • Weight loss – from malabsorption and decreased appetite.

Systemic / MEN‑1 Related Symptoms

  • Hyperparathyroidism – kidney stones, bone pain, fatigue.
  • Pituitary adenomas – visual changes, headaches, hormonal excess (e.g., prolactin, growth hormone).
  • Fatigue, anemia – secondary to chronic bleeding from ulcers.
  • Skin changes – facial angiofibromas or facial lentigines in some MEN‑1 families.

Red‑Flag Symptoms (Require urgent evaluation)

  • Sudden, severe abdominal pain (possible perforated ulcer).
  • Vomiting of blood (hematemesis) or black/tarry stools (melena).
  • Unexplained high fevers, jaundice, or signs of sepsis.

Causes and Risk Factors

Primary Cause

ZES results from gastrin‑secreting neuroendocrine tumors (gastrinomas). In MEN‑1‑associated ZES, the underlying driver is a germline mutation in the MEN1 gene, which leads to loss of function of the protein menin, a regulator of cell growth.

Risk Factors

  • Family history of MEN‑1 – first‑degree relatives have a 50 % chance of inheriting the mutation.
  • Known MEN1 pathogenic variant – identified through genetic testing.
  • Age – although gastrinomas can appear at any age, MEN‑1‑related tumors often develop before age 40.
  • Radiation exposure – theoretical risk; no strong data linking it to MEN‑1.

Diagnosis

Diagnosing ZES in the setting of MEN‑1 requires a combination of biochemical, imaging, and genetic studies.

1. Biochemical Testing

  • Fasting serum gastrin – levels >1000 pg/mL (10× upper limit) are highly suggestive; values >150 pg/mL with a gastric pH < 2 are diagnostic.3
  • Secretin stimulation test – a rise in gastrin >120 pg/mL after IV secretin confirms ZES when fasting gastrin is equivocal.
  • Gastric pH measurement – persistent acidity (<2) supports the diagnosis.

2. Imaging for Tumor Localization

  • Endoscopic ultrasound (EUS) – high sensitivity for small pancreatic/duodenal gastrinomas.
  • Multiphasic contrast‑enhanced CT or MRI – evaluates size, number, and metastasis.
  • Somatostatin receptor scintigraphy (OctreoScan) or 68Ga‑DOTATATE PET/CT – detects lesions expressing somatostatin receptors, especially useful for metastatic disease.
  • Selective arterial secretin injection (SASI) test – localizes gastrin‑producing tissue when non‑invasive imaging is negative.

3. Genetic Testing

All patients with ZES diagnosed before age 40, with a family history of endocrine tumors, or with multiple endocrine abnormalities should undergo MEN1 gene sequencing. Positive results confirm the hereditary form and guide family screening.

4. Additional Work‑up for MEN‑1 Manifestations

  • Serum calcium and parathyroid hormone (PTH) levels – screen for hyperparathyroidism.
  • Pituitary hormone panel and MRI – assess for adenomas.
  • Bone densitometry – monitor for osteoporosis secondary to hyperparathyroidism.

Treatment Options

Management aims to control acid hypersecretion, remove or control gastrinomas, and address other MEN‑1 tumors.

Acid‑Suppressive Therapy (First‑line)

  • High‑dose proton pump inhibitors (PPIs) – omeprazole 40–80 mg/day or equivalent; titrated to maintain gastric pH > 4.4
  • H2‑receptor antagonists – used as adjuncts if PPIs are insufficient.
  • Long‑term therapy is usually required; periodic “PPI holidays” are discouraged because ulcer recurrence is common.

Surgical Management

  • Curative resection – indicated for solitary, non‑metastatic gastrinomas (most often duodenal). Options include pancreas‑sparing duodenectomy or enucleation.
  • Debulking surgery – for metastatic disease to reduce tumor burden and improve symptoms.
  • Liver-directed therapies – radiofrequency ablation, embolization, or peptide‑receptor radionuclide therapy (PRRT) for hepatic metastases.

Medical Therapies for Unresectable/Metastatic Disease

  • Somatostatin analogues (octreotide, lanreotide) – inhibit gastrin release and may stabilize tumor growth.
  • Targeted therapy – everolimus (mTOR inhibitor) approved for advanced neuroendocrine tumors.
  • Chemotherapy – rarely used; streptozocin‑based regimens for aggressive disease.
  • PRRT – 177Lu‑DOTATATE shows promise in controlling metastatic gastrinomas with high somatostatin‑receptor expression.

Management of MEN‑1 Associated Tumors

  • Parathyroidectomy for primary hyperparathyroidism.
  • Transsphenoidal surgery or medical therapy for pituitary adenomas.

Lifestyle & Supportive Measures

  • Small, frequent meals; avoid foods that trigger acid (spicy, fatty, caffeine, alcohol).
  • Stay hydrated; replace electrolytes if chronic diarrhea.
  • Calcium and vitamin D supplementation if hyperparathyroidism is treated.

Living with Zollinger‑Ellison Syndrome (MEN‑1 Associated)

Daily Management Tips

  • Medication adherence – take PPIs exactly as prescribed; set daily reminders.
  • Regular monitoring – fasting gastrin and gastric pH every 6–12 months, or sooner if symptoms change.
  • Nutrition – work with a dietitian experienced in high‑acid conditions; consider low‑fat, low‑spice diets and enzyme supplementation if malabsorption is present.
  • Follow‑up schedule – at least annually with an endocrinologist, gastroenterologist, and surgeon familiar with MEN‑1.
  • Genetic counseling – essential for patients and at‑risk relatives; discuss testing, reproductive options, and surveillance protocols.
  • Support networks – MEN‑1 patient groups, online forums, and psychological counseling can reduce isolation.

Surveillance Recommendations (per NCCN & ENETEN guidelines)

  • Annual fasting gastrin and calcium/PTH levels.
  • Every 1–2 years: EUS or MRI for pancreas/duodenum, plus 68Ga‑DOTATATE PET/CT if prior metastases.
  • Every 2–3 years: Pituitary MRI, especially if hormonal symptoms emerge.

Prevention

Because ZES in MEN‑1 is genetically determined, primary prevention is not possible. However, risk reduction strategies focus on early detection and minimizing disease‑related complications.

  • Family screening – first‑degree relatives should have genetic testing and biochemical surveillance starting in childhood (usually at age 5‑10).
  • Avoid smoking and excessive alcohol – both can worsen ulcer disease.
  • Prompt treatment of hyperparathyroidism – reduces calcium‑driven stone formation and may lower tumor progression risk.
  • Vaccinations – keep hepatitis B and HPV up‑to‑date; patients on immunosuppressive therapies (e.g., everolimus) are more infection‑prone.

Complications

If untreated or inadequately controlled, ZES can lead to serious health issues.

  • Refractory peptic ulcer disease – can cause bleeding, perforation, or gastric outlet obstruction.
  • Gastro‑intestinal bleeding – chronic blood loss may cause iron‑deficiency anemia.
  • Malabsorption & nutritional deficiencies – especially of fat‑soluble vitamins (A, D, E, K) due to acid‑mediated pancreatic enzyme inactivation.
  • Metastatic gastrinoma – liver, lymph nodes, or bone metastases occur in up to 30–40 % of MEN‑1‑related cases.
  • Peptic ulcer perforation – surgical emergency with mortality up to 10 % if delayed.
  • Osteoporosis – from coexisting hyperparathyroidism.
  • Psychosocial impact – chronic disease burden can lead to anxiety, depression, and reduced quality of life.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience:
  • Sudden, severe abdominal pain that does not improve with medication.
  • Vomiting blood (bright red) or passing black, tarry stools.
  • Signs of shock – rapid heartbeat, fainting, cool clammy skin, or severe weakness.
  • High fever (>38.5 °C / 101.3 °F) with abdominal pain, suggesting perforation or infection.
  • Persistent vomiting that prevents you from keeping fluids down for more than 12 hours.
Prompt treatment is life‑saving and can prevent permanent organ damage.

Sources:

  1. Mayo Clinic. “Zollinger‑Ellison syndrome.” Updated 2023. Link.
  2. National Institute of Health, Genetics Home Reference. “MEN1 gene.” 2022. Link.
  3. American College of Gastroenterology. “Guideline for the Management of Gastric Acid Hypersecretion.” 2022. Link.
  4. Jensen RT et al. “Long‑term outcomes of high‑dose PPIs in Zollinger‑Ellison syndrome.” Gastroenterology 2021;161(2):445‑453.
  5. National Comprehensive Cancer Network (NCCN). “Neuroendocrine and Pancreatic Tumors Guidelines,” version 2.2024.
  6. World Health Organization. “Classification of endocrine tumors.” 2023.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References